/www.ncbi.nlm.nih.gov/pubmed/10102971I was interested (because of my age ha) and found the above NIH study which sounds good for us oldies.
Yes small study but good news anyway.
CONCLUSIONS: Mesalazine prophylaxis is necessary for the prevention of relapse by patients with ulcerative colitis in remission for less than 2 years, but this study casts doubt over whether continuous maintenance treatment is necessary in patients with prolonged clinical, endoscopic and histological remission, who are at very low risk of relapse.Post Edited (imagardener2) : 5/17/2017 7:54:28 PM (GMT-6)